Commonwealth slams Otsuka’s ‘inconsistent’ defences in Abilify patent case
The Commonwealth has urged the court to strike out the “inconsistent” pleadings of pharmaceutical firms Otsuka and Bristol-Myers Squibb in a patent case over the antipsychotic drug Abilify, calling them a “scandal” which could bring disrepute to the administration of justice.
For information on rights and reprints, contact subscriptions@lawyerly.com.au